Bromfenac
Company: Duract, Wyeth-Ayerst Laboratories
Approval Status: Approved July 1997
Treatment for: acute pain
Areas: Neurology; Oncology
| General Information | Side Effects |
General Information
Other Useful Resources
Bromfenac was cleared for marketing by the FDA on July 15, 1997. This provides an alternative to opioids for the management of acute pain. Bromfenac provides fast relief of acute pain without the side effects of opioid analgesics.
Side Effects
Possible adverse side effects include abdominal pain, headache, nausea, and vomiting.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
